Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

Inclusion Criteria:

1. Patient is male and aged >18 years old.

2. History of localized adenocarcinoma of the prostate with prior curative intenttreatment.

3. An elevated PSA, clinically suspicious for biochemically recurrent disease:

• Following Radical Prostatectomy: PSA >0.2 ng/mL

• Following Radiotherapy: nadir +2 ng/mL.

4. Potentially eligible for salvage therapy with curative intent.

Exclusion Criteria:

1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer <24 hours prior to the PET scan.

2. Patients currently receiving Androgen Deprivation Therapy (ADT).